Agios Drops Tebapivat SCD: No Edge Over Existing Drugs

Agios Pharmaceuticals (AGIO) will discontinue development of tebapivat in sickle cell disease after Phase 2 results showed hemoglobin response rates consistent with the drug class but no differentiation to justify continued development. The stock dropped roughly 7% on the news, closing at $36.28 on July 23.

The numbers

• Ticker: AGIO
• Stock price: $36.28 (close July 23, 2026)
• Market cap: $2.16 billion
• Drug: Tebapivat, an oral pyruvate kinase RP activator
• Indication: Sickle cell disease (discontinued)
• Trial phase: Phase 2 (stopped)

Agios’s chief medical officer Sarah Gheuens said the results “did not establish the level of differentiation we believe is necessary to support continued development.” Hemoglobin response rates were consistent with the class of pyruvate kinase activators, meaning the drug worked but didn’t work better than what already exists.

Why differentiation matters in sickle cell

Sickle cell disease is a blood disorder where red blood cells become rigid and sickle-shaped, causing painful vaso-occlusive crises and chronic anemia. The treatment field has become crowded. The FDA approved two gene therapies in late 2023: Casgevy (Vertex/CRISPR) and Lyfgenia (Bluebird). Novartis sells Adakveo (crizanlizumab) for crisis prevention. Pfizer’s Oxbryta (voxelotor) was withdrawn from the market in 2024 over safety concerns.

Pyruvate kinase activators work by boosting ATP production in red blood cells, improving their energy metabolism and reducing sickling. The mechanism improves hemoglobin but does not directly address the vaso-occlusive crisis pathway that drives the disease’s most severe complications. In a post-gene-therapy world, incremental hemoglobin improvements are not enough to compete.

What remains for Agios

Agios still has mitapivat, approved as Pyrukynd for pyruvate kinase deficiency, in the RISE UP Phase 3 trial for sickle cell disease. The Phase 2 portion of RISE UP met its primary endpoint of hemoglobin response, and the Phase 3 is ongoing with data expected in 2027. This is now Agios’s only SCD catalyst.

HC Wainwright maintained its Buy rating on Agios but lowered its price target from $54 to $52, implying 43% upside from the current price. The firm’s confidence rests on the Pyrukynd franchise in thalassemia and pyruvate kinase deficiency, not SCD.

What to watch

The RISE UP Phase 3 readout is the binary event for Agios in sickle cell. If mitapivat shows differentiated efficacy in Phase 3, the SCD franchise survives. If it replicates tebapivat’s undifferentiated profile, Agios exits sickle cell entirely. The risk: RISE UP’s Phase 2 data showed mixed results, with responses in some patient subgroups but not others. Watch for any Phase 3 enrollment updates or interim signals.

Agios’s core value sits in Pyrukynd’s approved indications and its pipeline in thalassemia. The SCD setback narrows the investment thesis but does not break it. The $52 analyst target still implies meaningful upside.

What It Means for the Trade

A 7% drop on a Phase 2 discontinuation is the market efficiently repricing an option that went to zero — tebapivat’s SCD value was never the core of the Agios thesis, but it was free optionality, and now it isn’t. The important detail is what the discontinuation actually told you: the drug worked on hemoglobin but showed no differentiation from the pyruvate kinase activator class — which at this point means no meaningful edge over mitapivat, Agios’s own approved molecule in the same mechanism. Agios was never going to run two PK activators against each other in SCD; without a potency or dosing edge, tebapivat was strategically redundant, and killing it frees trial resources rather than signaling a biology problem.

The read-through to mitapivat’s SCD program is the real trading question, and the answer is nuanced. Tebapivat’s failure does not predict mitapivat’s Phase 3 — different molecule, different trial, and RISE UP’s Phase 2 already met its hemoglobin primary — but it does confirm the class’s structural ceiling in sickle cell: PK activation improves hemoglobin and does not reliably move the vaso-occlusive crisis endpoint that regulators, payers, and prescribers actually care about. Mitapivat’s sNDA leans on hemoglobin as a surrogate for accelerated approval, and tebapivat’s undifferentiated hemoglobin-then-what profile is precisely the pattern that makes that surrogate argument hard. This is why the stock’s SCD-related volatility persists: each incremental data point either strengthens or weakens a surrogate-based regulatory story.

Mechanism and Market Context

Why differentiation is the whole game here: the sickle cell treatment field restructured itself around gene therapy in late 2023. Casgevy (Vertex/CRISPR) and Lyfgenia (Bluebird) offer functional cures for patients who can access them, crizanlizumab (Adakveo) attacks crisis frequency directly, and Oxbryta’s withdrawal after its own hemoglobin-based approval left a visible scar — a drug that improved a lab value, reached market, and got pulled over safety in 2024. That history matters for anyone underwriting hemoglobin-surrogate drugs in this indication now. In a field where the most severe patients may eventually be funneled toward curative options, an oral chronic therapy’s niche is the large population ineligible for or uninterested in transplant-conditioning gene therapy — but that niche is contested by other oral agents, including Novo’s etavopivat program with crisis-reduction data. An undifferentiated hemoglobin effect is not a product in that market.

The remaining Agios SCD story is mitapivat’s RISE UP Phase 3, with data expected in 2027 and the already-filed sNDA giving the regulatory calendar its next event. The company’s ability to run disciplined portfolio triage — cutting a program fast when differentiation fails, without pretending the data says something it doesn’t — is a management-quality signal worth something, even if the market prices it at zero on a down day.

Risks and What Could Go Wrong

1. The RISE UP Phase 3 reads out with the same undifferentiated profile, and Agios exits sickle cell entirely — removing a growth leg from the story.
2. Even a successful mitapivat SCD approval lands into a field where gene therapy, crizanlizumab, and Novo’s etavopivat set crisis-reduction expectations, compressing the label’s commercial relevance.
3. Pyrukynd’s growth in thalassemia and PKD is the actual floor for the stock, and any launch-execution wobble there removes the cushion under the SCD binary.
4. The mixed Phase 2 subgroup pattern — responders in some populations, not others — could resurface in Phase 3 and complicate the label.

Position read: tebapivat’s death narrowed the thesis but also clarified it — you own Agios for the approved franchise plus a binary regulatory catalyst, and you size the SCD leg as event risk, not as a core position. The HC Wainwright $52 target is a sell-side opinion anchored on the thalassemia/PKD base; build your own floor from the same numbers.

Sources: Agios press release, Reuters coverage, HCPlive analysis. See also our guide on how to read a clinical trial press release.